Similar articles for PMID: 27184943

Year	Number of Results
1902	1
1905	1
1910	1
1966	1
1994	1
1995	1
1996	1
1997	5
1999	6
2000	3
2001	4
2002	2
2003	4
2004	5
2005	9
2006	3
2007	8
2008	6
2009	5
2010	6
2011	6
2012	4
2013	6
2014	5
2015	6
2016	14
2017	6
2018	4
2019	6
2020	3
2021	11
2022	9
2023	2
2024	0

1

Acute and Late Genitourinary Toxicity after 72 Gy of Conventionally Fractionated Conformal Radiotherapy for Localised Prostate Cancer: Impact of Individual and Clinical Parameters.

Stankovic V, Džamic Z, Pekmezovic T, Tepavcevic DK, Dozic M, Saric M, Vuckovic S, Nikitovic M. Stankovic V, et al. Clin Oncol (R Coll Radiol). 2016 Sep;28(9):577-86. doi: 10.1016/j.clon.2016.04.041. Epub 2016 May 12. Clin Oncol (R Coll Radiol). 2016. PMID: 27184943

2

Toxicity of the lower gastrointestinal tract and its predictive factors after 72Gy conventionally fractionated 3D conformal radiotherapy of localized prostate cancer.

Stankovic V, Nikitovic M, Pekmezovic T, Pekmezovic D, Kisic Tepavcevic D, Stefanovic Djuric A, Saric M. Stankovic V, et al. J BUON. 2016 Sept-Oct;21(5):1224-1232. J BUON. 2016. PMID: 27837627 Free article.

3

Diabetes mellitus: a predictor for late radiation morbidity.

Herold DM, Hanlon AL, Hanks GE. Herold DM, et al. Int J Radiat Oncol Biol Phys. 1999 Feb 1;43(3):475-9. doi: 10.1016/s0360-3016(98)00460-x. Int J Radiat Oncol Biol Phys. 1999. PMID: 10078625

4

Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.

Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, Amols HI. Zelefsky MJ, et al. Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1124-9. doi: 10.1016/j.ijrobp.2007.11.044. Int J Radiat Oncol Biol Phys. 2008. PMID: 18313526

5

Dose escalation in prostate radiotherapy up to 82 Gy using simultaneous integrated boost: direct comparison of acute and late toxicity with 3D-CRT 74 Gy and IMRT 78 Gy.

Dolezel M, Odrazka K, Vaculikova M, Vanasek J, Sefrova J, Paluska P, Zouhar M, Jansa J, Macingova Z, Jarosova L, Brodak M, Moravek P, Hartmann I. Dolezel M, et al. Strahlenther Onkol. 2010 Apr;186(4):197-202. doi: 10.1007/s00066-010-2065-x. Epub 2010 Mar 26. Strahlenther Onkol. 2010. PMID: 20354663

6

Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: A randomized clinical trial.

Viani GA, Viana BS, Martin JE, Rossi BT, Zuliani G, Stefano EJ. Viani GA, et al. Cancer. 2016 Jul 1;122(13):2004-11. doi: 10.1002/cncr.29983. Epub 2016 Mar 29. Cancer. 2016. PMID: 27028170 Free article. Clinical Trial.

7

Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.

Peeters ST, Heemsbergen WD, van Putten WL, Slot A, Tabak H, Mens JW, Lebesque JV, Koper PC. Peeters ST, et al. Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1019-34. doi: 10.1016/j.ijrobp.2004.07.715. Int J Radiat Oncol Biol Phys. 2005. PMID: 15752881 Clinical Trial.

8

Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy.

Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg D, Pollack A. Feigenberg SJ, et al. Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):397-405. doi: 10.1016/j.ijrobp.2004.10.021. Int J Radiat Oncol Biol Phys. 2005. PMID: 15890581

9

Acute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: initial report of American College of Radiology Phase II study 03-12.

Coen JJ, Bae K, Zietman AL, Patel B, Shipley WU, Slater JD, Rossi CJ. Coen JJ, et al. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1005-9. doi: 10.1016/j.ijrobp.2010.06.047. Epub 2010 Oct 6. Int J Radiat Oncol Biol Phys. 2011. PMID: 20932675 Clinical Trial.

10

Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.

Aluwini S, Pos F, Schimmel E, van Lin E, Krol S, van der Toorn PP, de Jager H, Dirkx M, Alemayehu WG, Heijmen B, Incrocci L. Aluwini S, et al. Lancet Oncol. 2015 Mar;16(3):274-83. doi: 10.1016/S1470-2045(14)70482-6. Epub 2015 Feb 3. Lancet Oncol. 2015. PMID: 25656287 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

140 results

Results by year